BRIEF-OncoSec Is Encouraged After FDA Meeting To Discuss Proposed Neoadjuvant Melanoma Clinical Program

Reuters2023-05-16

May 16 (Reuters) - OncoSec Medical Inc :

* ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS PROPOSED NEOADJUVANT MELANOMA CLINICAL PROGRAM

* ONCOSEC MEDICAL INC - TODAY ANNOUNCED A TYPE C MEETING HELD WITH FDA ON MAY 15

* ONCOSEC MEDICAL - TALK WITH FDA FOLLOWS RELEASE OF INTERIM DATA FROM ONGOING INVESTIGATOR-SPONSORED TRIAL IN COMBINATION WITH INTRAVENOUS NIVOLUMAB

Source text for Eikon: Further company coverage:

((Reuters.Brief@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2335806462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-05-16 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2335806462","market":"us","top_or_hot":-1,"title":"BRIEF-OncoSec Is Encouraged After FDA Meeting To Discuss Proposed Neoadjuvant Melanoma Clinical Program","media":"Reuters","content":"<html><body><p>May 16 (Reuters) - OncoSec Medical Inc   :</p><p>   * ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS PROPOSED NEOADJUVANT MELANOMA CLINICAL PROGRAM</p><p>   * ONCOSEC MEDICAL INC -  TODAY ANNOUNCED A TYPE C MEETING HELD WITH FDA ON MAY 15</p><p>   * ONCOSEC MEDICAL -  TALK WITH FDA FOLLOWS RELEASE OF INTERIM DATA FROM ONGOING INVESTIGATOR-SPONSORED TRIAL IN COMBINATION WITH INTRAVENOUS NIVOLUMAB</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Brief@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-OncoSec Is Encouraged After FDA Meeting To Discuss Proposed Neoadjuvant Melanoma Clinical Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-OncoSec Is Encouraged After FDA Meeting To Discuss Proposed Neoadjuvant Melanoma Clinical Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-16 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 16 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS PROPOSED NEOADJUVANT MELANOMA CLINICAL PROGRAM   * ONCOSEC MEDICAL INC -  TODAY ANNOUNCED A TYPE C ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2335806462","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2335806462","pubTimestamp":1684240109,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 16 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS PR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc.","BK4023":"应用软件","BK4007":"制药","BK4196":"保健护理服务","BK4082":"医疗保健设备","LHDX":"Lucira Health, Inc.","ONTF":"ON24, Inc.","BK4139":"生物科技","LABP":"Landos Biopharma, Inc."},"translate_title":"简介——OncoSec在FDA会议后被鼓励讨论新辅助黑色素瘤临床计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCS":0.9,"APR":0.85,"CGEM":0.85,"LABP":0.85,"LHDX":0.85,"ONTF":0.85,"SANA":0.85},"content_text":"May 16 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS PROPOSED NEOADJUVANT MELANOMA CLINICAL PROGRAM   * ONCOSEC MEDICAL INC -  TODAY ANNOUNCED A TYPE C MEETING HELD WITH FDA ON MAY 15   * ONCOSEC MEDICAL -  TALK WITH FDA FOLLOWS RELEASE OF INTERIM DATA FROM ONGOING INVESTIGATOR-SPONSORED TRIAL IN COMBINATION WITH INTRAVENOUS NIVOLUMABSource text for Eikon:    Further company coverage:    ((Reuters.Brief@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2335806462"}